The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.
HDAC inhibitor‐based therapies: Can we interpret the code?
Open accessAbstract
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone deacetylases (HDACs). HDACs regulate the acetylation of histones in nucleosomes, which mediates changes in chromatin conformation, leading to regulation of gene expression. HDACs also regulate the acetylation status of a variety of other non‐histone substrates, including key tumour suppressor proteins and oncogenes. Histone deacetylase inhibitors (HDIs) are potent anti‐proliferative agents which modulate acetylation by targeting histone deacetylases. Interest is increasing in HDI‐based therapies and so far, two HDIs, vorinostat (SAHA) and romidepsin (FK228), have been approved for treating cutaneous T‐cell lymphoma (CTCL). Others are undergoing clinical trials. Treatment with HDIs prompts tumour cells to undergo apoptosis, and cell‐based studies have shown a number of other outcomes to result from HDI treatment, including cell‐cycle arrest, cell differentiation, anti‐angiogenesis and autophagy. However, our understanding of the key pathways through which HDAC inhibitors affect tumour cell growth remains incomplete, which has hampered progress in identifying malignancies other than CTCL which are likely to respond to HDI treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wu, L.-M., Yang, Z., Zhou, L., Zhang, F., Xie, H., Feng, X., Wu, J., & Zheng, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014460 · Cited by 106
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Regulation mechanisms and signaling pathways of autophagy
He, C., & Klionsky, D. J. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102808-114910 · Cited by 3,609
Self-eating and self-killing: crosstalk between autophagy and apoptosis
Maiuri, M. C., Zalckvar, E., Kimchi, A., & Kroemer, G. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2239 · Cited by 3,577
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
Molecular chaperones in protein folding and proteostasis
Hartl, F. U., Bracher, A., & Hayer-Hartl, M. (2011) · Nature · doi:10.1038/nature10317 · Cited by 3,381
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H., & Johansen, T. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200507002 · Cited by 3,276
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Aggresomes: A Cellular Response to Misfolded Proteins
Johnston, J. A., Ward, C. L., & Kopito, R. R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.7.1883 · Cited by 2,148
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
HIF-1α is essential for myeloid cell-mediated inflammation
Cramer, T., Yamanishi, Y., Clausen, B. E., Förster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00154-5 · Cited by 2,046
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
The roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625
Network organization of the human autophagy system
Behrends, C., Sowa, M. E., Gygi, S. P., & Harper, J. W. (2010) · Nature · doi:10.1038/nature09204 · Cited by 1,554
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153
The Double-Edged Sword of Autophagy Modulation in Cancer
White, E., & DiPaola, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5023 · Cited by 1,138
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis
Dai, C., Whitesell, L., Rogers, A. B., & Lindquist, S. (2007) · Cell · doi:10.1016/j.cell.2007.07.020 · Cited by 826
Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis
Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 804
Autophagy as a target for anticancer therapy
Janku, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803
HDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy
Lee, J., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y., Pandey, U. B., Kaushik, S., Tresse, E., Lu, J., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.405 · Cited by 756
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 712
Regulation of E2F1 activity by acetylation
Martínez-Balbás, M. A., Bauer, U.-M., Nielsen, S. J., Brehm, A., & Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.662 · Cited by 671
Class II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1
Westerheide, S. D., Anckar, J., Stevens, S. M., Sistonen, L., & Morimoto, R. I. (2009) · Science · doi:10.1126/science.1165946 · Cited by 639
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
Miller, K. M., Tjeertes, J. V., Coates, J., Legube, G., Polo, S. E., Britton, S., & Jackson, S. P. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1899 · Cited by 629
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559
HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the β-catenin–TCF interaction
Ye, F., Chen, Y., Hoang, T., Montgomery, R. L., Zhao, X.-H., Bu, H., Hu, T., Taketo, M. M., van Es, J. H., Clevers, H., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2333 · Cited by 559
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
(2003) · PubMed · Cited by 519
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Peyssonnaux, C., Cejudo-Martin, P., Doedens, A., Zinkernagel, A. S., Johnson, R. S., & Nizet, V. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7516 · Cited by 480
Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 474
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
Verma, R., Oania, R., Graumann, J., & Deshaies, R. J. (2004) · Cell · doi:10.1016/j.cell.2004.06.014 · Cited by 449
Tan, J. M. M., Wong, E. S. P., Kirkpatrick, D. S., Pletnikova, O., Ko, H. S., Tay, S.-P., Ho, M. W. L., Troncoso, J., Gygi, S. P., Lee, M. K., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm320 · Cited by 445
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Autophagy in Cancer: Good, Bad, or Both?
Hippert, M. M., O'Toole, P. S., & Thorburn, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1597 · Cited by 396
The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
Liu, T., Liu, P. Y., & Marshall, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3365 · Cited by 384
Bhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z.-W., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 372
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates
Boyault, C., Zhang, Y., Fritah, S., Caron, C., Gilquin, B., Kwon, S. H., Garrido, C., Yao, T.-P., Vourc’h, C., Matthias, P., et al. (2007) · Genes & Development · doi:10.1101/gad.436407 · Cited by 368
Taddei, A., Maison, C., Roche, D., & Almouzni, G. (2001) · Nature Cell Biology · doi:10.1038/35055010 · Cited by 361
Sirtuins mediate mammalian metabolic responses to nutrient availability
Chalkiadaki, A., & Guarente, L. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.225 · Cited by 346
Roger, T., Lugrin, J., Le Roy, D., Goy, G., Mombelli, M., Koessler, T., Ding, X. C., Chanson, A.-L., Reymond, M. K., Miconnet, I., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284711 · Cited by 341
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Olzmann, J. A., Li, L., Chudaev, M. V., Chen, J., Perez, F. A., Palmiter, R. D., & Chin, L.-S. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611128 · Cited by 339
Leoni, F., Fossati, G., Lewis, E. C., Lee, J.-K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., et al. (2005) · Molecular Medicine · doi:10.2119/2006-00005.dinarello · Cited by 337
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
Self-citationFournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M., Watkins, C. J., Thangue, N. B. L., & Brown, R. E. (2003) · PubMed · Cited by 312
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 299
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 291
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 281
A phosphorylation-acetylation switch regulates STAT1 signaling
Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K.-H., Stauber, R. H., Böhmer, F. D., & Heinzel, T. (2009) · Genes & Development · doi:10.1101/gad.479209 · Cited by 281
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Morselli, E., Tasdemir, E., Chiara Maiuri, M., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 277
Nimmanapalli, R., Fuino, L., Bali, P., Gasparetto, M., Glozak, M. A., Tao, J., Moscinski, L. C., Smith, C. A., Wu, J., Jove, R., et al. (2003) · PubMed · Cited by 276
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase 1
Zupkovitz, G., Tischler, J., Posch, M., Sadzak, I., Ramsauer, K., Egger, G., Grausenburger, R., Schweifer, N., Chiocca, S., Decker, T., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01220-06 · Cited by 263
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Lee, Y.-S., Lim, K.-H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., Ordentlich, P., Wang, X.-F., Counter, C. M., & Yao, T.-P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0188 · Cited by 260
Differential expression of selected histone modifier genes in human solid cancers
Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 259
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5429-5444.2005 · Cited by 245
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C. E., Buhl-Jensen, P., Brown, R., Evans, T. R. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1786 · Cited by 244
Modulation of radiation response by histone deacetylase inhibition
Chinnaiyan, P., Vallabhaneni, G., Armstrong, E., Huang, S.-M., & Harari, P. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.088 · Cited by 243
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Rosato, R. R., Almenara, J. A., Dai, Y., & Grant, S. (2003) · PubMed · Cited by 232
Badros, A., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J. J., Espinoza-Delgado, I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2850 · Cited by 231
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 228
Brogdon, J. L., Xu, Y., Szabo, S. J., An, S., Buxton, F., Cohen, D., & Huang, Q. (2007) · Blood · doi:10.1182/blood-2006-04-019711 · Cited by 227
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis
Wilting, R. H., Yanover, E., Heideman, M. R., Jacobs, H., Horner, J., van der Torre, J., DePinho, R. A., & Dannenberg, J. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.136 · Cited by 226
Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., & Gattermann, N. (2006) · Cancer · doi:10.1002/cncr.21552 · Cited by 224
Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation
Carew, J. S., Medina, E. C., Esquivel II, J. A., Mahalingam, D., Swords, R., Kelly, K., Zhang, H., Huang, P., Mita, A. C., Mita, M. M., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00832.x · Cited by 219
HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
Wilson, A. J., Byun, D.-S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., Figueroa, M., Melnick, A., Kao, G. D., Augenlicht, L. H., et al. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0139 · Cited by 214
Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213
Chang, H.-M., Paulson, M., Holko, M., Rice, C. M., Williams, B. R. G., Marié, I., & Levy, D. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400567101 · Cited by 212
Dequiedt, F., Kasler, H., Fischle, W., Kiermer, V., Weinstein, M., Herndier, B. G., & Verdin, E. (2003) · Immunity · doi:10.1016/s1074-7613(03)00109-2 · Cited by 212
Acetylation-Dependent Signal Transduction for Type I Interferon Receptor
Tang, X., Gao, J.-S., Guan, Y.-J., McLane, K. E., Yuan, Z.-L., Ramratnam, B., & Chin, Y. E. (2007) · Cell · doi:10.1016/j.cell.2007.07.034 · Cited by 211
Histone Deacetylase 6 Regulates Growth Factor-Induced Actin Remodeling and Endocytosis
Gao, Y.-S., Hubbert, C. C., Lu, J., Lee, Y.-S., Lee, J.-Y., & Yao, T.-P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00393-07 · Cited by 209
Oxidative Stress Induces Parallel Autophagy and Mitochondria Dysfunction in Human Glioma U251 Cells
Zhang, H., Kong, X., Kang, J., Su, J., Li, Y., Zhong, J., & Sun, L. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp101 · Cited by 208
Rodriguez-Rocha, H., Garcia-Garcia, A., Panayiotidis, M. I., & Franco, R. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.03.007 · Cited by 198
Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., et al. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190701817258 · Cited by 190
Requirement of Histone Deacetylase Activity for Signaling by STAT1
Klampfer, L., Huang, J., Swaby, L.-A., & Augenlicht, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401359200 · Cited by 189
Rao, R., Fiskus, W., Yang, Y., Lee, P., Joshi, R., Fernandez, P., Mandawat, A., Atadja, P., Bradner, J. E., & Bhalla, K. (2008) · Blood · doi:10.1182/blood-2008-03-143644 · Cited by 188
Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
Bolderson, E., Richard, D. J., Zhou, B.-B. S., & Khanna, K. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0096 · Cited by 187
Halili, M. A., Andrews, M. R., Labzin, L. I., Schroder, K., Matthias, G., Cao, C., Lovelace, E., Reid, R. C., Le, G. T., Hume, D. A., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0509363 · Cited by 186
Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp270 · Cited by 184
Mottet, D., Pirotte, S., Lamour, V., Hagedorn, M., Javerzat, S., Bikfalvi, A., Bellahcène, A., Verdin, E. M., & CASTRONOVO, V. (2008) · Oncogene · doi:10.1038/onc.2008.371 · Cited by 180
Bode, K. A., Schroder, K., Hume, D. A., Ravasi, T., Heeg, K., Sweet, M. J., & Dalpke, A. H. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02678.x · Cited by 180
HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
Li, Y., Zhang, X., Polakiewicz, R. D., Yao, T.-P., & Comb, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c700185200 · Cited by 173
The Role of Mammalian Sirtuins in the Regulation of Metabolism, Aging, and Longevity
Satoh, A., Stein, L., & Imai, S. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-21631-2_7 · Cited by 172
Dequiedt, F., Van Lint, J., Lecomte, E., Van Duppen, V., Seufferlein, T., Vandenheede, J. R., Wattiez, R., & Kettmann, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042034 · Cited by 172
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171 · cited 1×
“To act on neurons, it is important for HDIs to cross the bloodebrain barrier, which is the case for valproic acid, SAHA, MS-275, sodium butyrate and phenyl butyrate (Grayson et al., 2010).”
BackgroundFantin, V. R., Loboda, A., Paweletz, C. P., Hendrickson, R. C., Pierce, J. W., Roth, J. A., Li, L., Gooden, F., Korenchuk, S., Hou, X. S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6091 · Cited by 170
Regulation of the HIF-1α stability by histone deacetylases
Kim, S. H., Jeong, J.-W., Park, J. Y., Lee, J., Seo, J., Jung, B., Bae, M., & Kim, K. (2007) · Oncology Reports · doi:10.3892/or.17.3.647 · Cited by 170
Miyake, K., Yoshizumi, T., Imura, S., Sugimoto, K., Batmunkh, E., Kanemura, H., Morine, Y., & Shimada, M. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815f2c2a · Cited by 169
Development of vorinostat: Current applications and future perspectives for cancer therapy
Richon, V. M., Garcia-Vargas, J., & Hardwick, J. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.002 · Cited by 169
Calpains Can Do It Alone: Implications for Cancer Therapy
guicciardi, M. E., & Gores, G. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.2.349 · Cited by 164
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Пили, Р., Salumbides, B. C., Zhao, M., Altiok, S., Qian, D. Z., Zwiebel, J. A., Carducci, M. A., & Rudek, M. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.527 · Cited by 160
Kalac, M., Scotto, L., Marchi, E., Amengual, J., Seshan, V. E., Bhagat, G., Ulahannan, N., Leshchenko, V. V., Temkin, A. M., Parekh, S., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336891 · Cited by 158
Urbich, C., Rössig, L., Kaluza, D., Potente, M., Boeckel, J., Knau, A., Diehl, F., Geng, J.-G., Hofmann, W., Zeiher, A. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-196485 · Cited by 157
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Khan, O. A., Fotheringham, S. A., Wood, V. H. J., Stimson, L., Zhang, C., Pezzella, F., Duvic, M. A., Kerr, D. J., & Thangue, N. B. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913912107 · Cited by 157
Frew, A. J., Lindemann, R. K., Martin, B. P., Clarke, C. J. P., Sharkey, J., Anthony, D. A., Banks, K.-M., Haynes, N. M., Gangatirkar, P., Stanley, K. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801868105 · Cited by 155
Kachhap, S. K., Rosmus, N., Collis, S. J., Kortenhorst, M. S. Q., Wissing, M. D., Hedayati, M. A., Shabbeer, S., Mendonca, J., Deangelis, J., Marchionni, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011208 · Cited by 154
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Bommareddy, A., Hahm, E.-R., Xiao, D., Powolny, A., Fisher, A. L., Jiang, Y., & Singh, S. V. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4344 · Cited by 152
A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer
Stadler, W. M., Margolin, K. A., Ferber, S., McCulloch, W. F., & Thompson, J. A. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.018 · Cited by 151
Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors
Guerrant, W., Patil, V., Canzoneri, J. C., & Oyelere, A. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm200799p · Cited by 149
HDAC inhibitor-based therapies and haematological malignancy
Stimson, L., Wood, V. H. J., Khan, O. A., Fotheringham, S. A., & Thangue, N. B. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn792 · Cited by 148
Histone deacetylase 1 mRNA expression in lung cancer
Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Kiriyama, M., Fukai, I., Yamakawa, Y., & Fujii, Y. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.021 · Cited by 145
Dowdy, S. C., Jiang, S., Zhou, X., Hou, X., Jin, F., Podratz, K. C., & Jiang, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0209 · Cited by 143
Bruzzese, F., Leone, A., Rocco, M., Carbone, C., Piro, G., Caraglia, M., Gennaro, E. D., & Budillon, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22574 · Cited by 143
Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
Petruccelli, L. A., Dupéré-Richer, D., Pettersson, F., Retrouvey, H., Skoulikas, S., & Miller, W. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020987 · Cited by 141
Nusinzon, I., & Horvath, C. M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3106-3113.2006 · Cited by 140
Minamiya, Y., Ono, T., Saito, H., Takahashi, N., Ito, M., Mitsui, M., Motoyama, S., & Ogawa, J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.019 · Cited by 138
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Self-citationMocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Boumber, Y., Younes, A., & Garcia‐Manero, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.577737 · Cited by 137
Niesvizky, R., Ely, S. A., Mark, T. M., Aggarwal, S., Gabrilove, J. L., Wright, J. J., Chen‐Kiang, S., & Sparano, J. A. (2010) · Cancer · doi:10.1002/cncr.25584 · Cited by 133
Histone deacetylase inhibitors and genomic instability
Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 132
Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130
Chávez-Blanco, A. D., Segura-Pacheco, B. A., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Cetina, L., Candelaria, M., de León, D. F. C., González‐Fierro, A., García‐López, P., Zambrano, P., et al. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-22 · Cited by 129
Bono, J. S. D., Kristeleit, R. S., Tolcher, A. W., Fong, P. C. C., Pacey, S., Karavasilis, V., Mita, M. M., Shaw, H. M., Workman, P., Kaye, S. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0376 · Cited by 126
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma
Buglio, D., Khaskhely, N. M., Voo, K. S., Martínez-Valdez, H., Liu, Y., & Younes, A. (2011) · Blood · doi:10.1182/blood-2010-08-303701 · Cited by 119
Cha, T., Chuang, M., Wu, S., Sun, G., Chang, S., Yü, D., Huang, S., Huan, S. K.-H., Cheng, T., Chen, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1918 · Cited by 118
Feng, R., Oton, A. B., Mapara, M. Y., Anderson, G., Belani, C. P., & Lentzsch, S. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06772.x · Cited by 114
Genetic dissection of histone deacetylase requirement in tumor cells
Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903139106 · Cited by 112
Marquard, L., Gjerdrum, L. M. R., Christensen, I. J., Jensen, P. B., Sehested, M., & Ralfkiaer, E. M. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03109.x · Cited by 109
Yamamoto, S., Tanaka, K., Sakimura, R., Okada, T., Nakamura, T., Li, Y., Takasaki, M., Nakabeppu, Y., & Iwamoto, Y. (2008) · PubMed · Cited by 107
Blattmann, C., Oertel, S., Ehemann, V., Thiemann, M., Huber, P. E., Bischof, M., Witt, O., Deubzer, H. E., Kulozik, A. E., Debus, J., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.010 · Cited by 107
Histone Deacetylases 9 and 10 Are Required for Homologous Recombination
Kotian, S., Liyanarachchi, S., Zelent, A., & Parvin, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.194233 · Cited by 104
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
Khan, O. A., & Thangue, N. B. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1238 · Cited by 103
Hrzenjak, A., Kremser, M., Strohmeier, B., Moinfar, F., Zatloukal, K., & Denk, H. (2008) · The Journal of Pathology · doi:10.1002/path.2434 · Cited by 103
Park, J., Kim, S.-H., Choi, M.-C., Lee, J., Oh, D., Im, S., Bang, Y., & Kim, T.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.056 · Cited by 99
Biomarkers for predicting clinical responses to HDAC inhibitors
Stimson, L., & Thangue, N. B. L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.016 · Cited by 98
Bhalla, S., Balasubramanian, S., David, K. A., Sirisawad, M., Buggy, J. J., Mauro, L. A., Prachand, S., Miller, R. A., Gordon, L. I., & Evens, A. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2365 · Cited by 98
Zika, E., Greer, S. F., Zhu, X.-S., & Ting, J. P. ‐. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.9.3091-3102.2003 · Cited by 97
Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
Rikiishi, H. (2011) · BioMed Research International · doi:10.1155/2011/830260 · Cited by 94
Into, T., Inomata, M., Niida, S., Murakami, Y., & Shibata, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.126904 · Cited by 92
A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma
Mohammed, T. A., Holen, K. D., Jaskula‐Sztul, R., Mulkerin, D. L., Lubner, S. J., Schelman, W. R., Eickhoff, J. C., Chen, H., & LoConte, N. K. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0031 · Cited by 92
Zhang, F., Zhang, T., Teng, Z., Zhang, R., Wang, J., & Mei, Q. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8143 · Cited by 89
Arts, J., Angibaud, P. R., Mariën, A., Floren, W., Janssens, B., King, P., Dun, J. V., Janssen, L., Geerts, T., Tuman, R. W., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604025 · Cited by 89
Moniot, S., Weyand, M., & Steegborn, C. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00016 · Cited by 89
Histone deacetylase inhibitors induce mitotic slippage
Stevens, F., Beamish, H., Warrener, R., & Gabrielli, B. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210779 · Cited by 85
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T., & Witt, O. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241658 · Cited by 85
Nolan, L., Johnson, P., Ganesan, A., Packham, G., & Crabb, S. J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604557 · Cited by 85
Nguyen, T., Dai, Y., Attkisson, E., Kramer, L. B., Jordan, N., Nguyen, N., Kolluri, N., Müschen, M., & Grant, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0234 · Cited by 84
Kong, X., Fang, M., Li, P., Fang, F., & Xu, Y. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.023 · Cited by 83
Lorin, S., Borges, A., Santos, L. R. D., Souquère, S., Pierron, G., Ryan, K. M., Codogno, P., & Djavaheri‐Mergny, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1270 · Cited by 82
Whitehead, R. P., Rankin, C. J., Hoff, P. M., Gold, P. J., Billingsley, K. G., Chapman, R., Wong, L., Ward, J. H., Abbruzzese, J. L., & Blanke, C. D. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9190-8 · Cited by 80
Mueller, S., Yang, X., Sottero, T. L., Gragg, A., Prasad, G., Polley, M. C., Weiss, W. A., Matthay, K. K., Davidoff, A. M., DuBois, S. G., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.010 · Cited by 80
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities
Konstantinopoulos, P. A., Vandoros, G. P., & Papavassiliou, A. G. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0182-5 · Cited by 78
Keynote review: Chromatin control and cancer-drug discovery: realizing the promise
Inche, A. G., & Thangue, N. B. L. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03691-3 · Cited by 77
Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Fulda, S. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783769355 · Cited by 75
Borbone, E., Berlingieri, M. T., Bellis, F. D., Nebbioso, A., Chiappetta, G., Mai, A., Altucci, L., & Fusco, A. (2009) · Oncogene · doi:10.1038/onc.2009.306 · Cited by 73
Wang, Z., Xu, L., Duan, Z., Zeng, L., YAN, N., & Peng, Z. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.05.034 · Cited by 70
Sun, X., Lei, W., Chen, Q., & Terek, R. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.019091 · Cited by 66
Pohlman, B. L., Advani, R. H., Duvic, M. A., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Ben‐Yehuda, D., Beylot-Barry, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.920.920 · Cited by 66
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Marchion, D. C., Biçaku, E., Turner, J. G., Schmitt, M. L., Morelli, D., & Münster, P. N. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0985 · Cited by 65
Angiogenesis in hematologic malignancies
Moehler, T. M., Neben, K., Ho, A. D., & Goldschmidt, H. (2001) · Annals of Hematology · doi:10.1007/s00277-001-0398-3 · Cited by 63
Valproic Acid in the Complex Therapy of Malignant Tumors
Hřebačková, J., Hraběta, J., & Eckschlager, T. (2010) · Current Drug Targets · doi:10.2174/138945010790711923 · Cited by 58
Sp1-Mediated TRAIL Induction in Chemosensitization
Xu, J., Zhou, J.-Y., Wei, W., Philipsen, S., & Wu, G. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0657 · Cited by 55
Histone deacetylase 1 expression in gastric cancer
Mori, M. (2011) · Oncology Reports · doi:10.3892/or.2011.1361 · Cited by 55
Effect of valproic acid on the outcome of glioblastoma multiforme
Tsai, H., Wei, K., Tsai, C., Huang, Y., Chen, P., Chen, S., Lin, Y.-J., & Lee, S. (2011) · British Journal of Neurosurgery · doi:10.3109/02688697.2011.638996 · Cited by 53
Schutter, H. D., Kimpe, M., Isebaert, S. F., & Nuyts, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.032 · Cited by 52
Huang, X., Wang, S., Lee, C., Yang, X., & Liu, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.019 · Cited by 51
Lü, J., Sun, H., Wang, X., Liu, C., Xu, X., Li, F., & Huang, B. (2005) · Cytokine · doi:10.1016/j.cyto.2005.03.001 · Cited by 50
Theocharis, S. E., Klijanienko, J., Giaginis, C., Rodriguez, J., Jouffroy, T., Girod, A., Alexandrou, P. T., & Sastre‐Garau, X. (2011) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2011.01031.x · Cited by 49
Noro, R., Miyanaga, A., Minegishi, Y., Okano, T., Seike, M., Soeno, C., Kataoka, K., Matsuda, K., Yoshimura, A., & Gemma, A. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01559.x · Cited by 42
Hurwitz, J. L., Stasik, I., Kerr, E. M., Holohan, C., Redmond, K. M., McLaughlin, K. M., Busacca, S., Barbone, D., Broaddus, V. C., Gray, S. G., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.009 · Cited by 42
Lian, Z., Xu, Y., Wang, X., Gong, J., & Liu, Z. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2010.12.035 · Cited by 41
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Ketone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966
β-Hydroxybutyrate: A Signaling Metabolite
Newman, J. C., & Verdin, E. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064916 · Cited by 872
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
Brocks, D., Schmidt, C. R., Daskalakis, M., Jang, H. S., Shah, N. M., Li, D., Li, J., Zhang, B., Hou, Y., Laudato, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3889 · Cited by 339
Metadata
- Authors
- New, M., Olzscha, H., & La Thangue, N. B.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2012-10-23
- Volume
- 6
- Issue
- 6
- Pages
- 637-656
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2014364284
- Cited by
- 310
- References
- 205
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.